Syneron Medical Ltd. (NASDAQ: ELOS) received US Food and Drug Administration (FDA) clearance for elōs Plus, a multi-platform system featuring the company's proprietary elōs technology of optical energy and bi-polar radiofrequency. The FDA clearance follows on the recent international launch in Europe and Asia. The system is customizable or upgradable utilizing up to eight in-demand aesthetic applicators, which also includes the company's Sublative and Sublime applications. The intuitive fifteen-inch touch screen offers guided treatment modes for all applications and is equipped with the most popular features from recent Syneron models such as the proprietary Active Dermal Monitoring, Intelligent Feedback System, and Sublative iD.